Search Results

There are 72664 results for: content related to: Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities

  1. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure

    Movement Disorders

    Volume 21, Issue 10, October 2006, Pages: 1578–1594, Susan H. Fox, Anthony E. Lang and Jonathan M. Brotchie

    Version of Record online : 27 JUL 2006, DOI: 10.1002/mds.20936

  2. Nondopaminergic mechanisms in levodopa-induced dyskinesia

    Movement Disorders

    Volume 20, Issue 8, August 2005, Pages: 919–931, Jonathan M. Brotchie

    Version of Record online : 8 JUL 2005, DOI: 10.1002/mds.20612

  3. You have free access to this content
    Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

    British Journal of Pharmacology

    Volume 164, Issue 4, October 2011, Pages: 1357–1391, Susan Duty and Peter Jenner

    Version of Record online : 26 SEP 2011, DOI: 10.1111/j.1476-5381.2011.01426.x

  4. Dyskinesia Induced by Levodopa and Dopamine Agonists in Patients with Parkinson's Disease

    Drug Induced Movement Disorders, Second Edition

    John G. Nutt, Matthew A. Brodsky, Pages: 313–350, 2008

    Published Online : 14 JAN 2008, DOI: 10.1002/9780470753217.ch13

  5. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation

    Movement Disorders

    Volume 17, Issue 5, September/October 2002, Pages: 887–901, Lance A. Smith, Banu C. Tel, Michael J. Jackson, Matthew J. Hansard, Rogelio Braceras, Céline Bonhomme, Claire Chezaubernard, Susanna Del Signore, Sarah Rose and Peter Jenner

    Version of Record online : 7 MAY 2002, DOI: 10.1002/mds.10200

  6. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: Effect of dose, frequency of administration, and brain exposure

    Movement Disorders

    Volume 18, Issue 5, May 2003, Pages: 487–495, Lance A. Smith, Michael J. Jackson, Matthew J. Hansard, Eleni Maratos and Peter Jenner

    Version of Record online : 28 MAR 2003, DOI: 10.1002/mds.10394

  7. Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate

    Movement Disorders

    Volume 16, Issue 2, March 2001, Pages: 202–207, G.M. Petzinger, M. Quik, E. Ivashina, M.W. Jakowec, M. Jakubiak, D. Di Monte and J.W. Langston

    Version of Record online : 14 MAR 2001, DOI: 10.1002/mds.1075

  8. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Version of Record online : 19 JUN 2012, DOI: 10.1002/mds.25051

  9. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan

    Movement Disorders

    Volume 16, Issue 4, July 2001, Pages: 642–650, Susan H. Fox, Brian Henry, Micheal P. Hill, David Peggs, Alan R. Crossman and Jonathan M. Brotchie

    Version of Record online : 16 JUL 2001, DOI: 10.1002/mds.1148

  10. The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease

    Movement Disorders

    Volume 26, Issue 7, June 2011, Pages: 1225–1233, James B. Koprich, Susan H. Fox, Tom H. Johnston, Allan Goodman, Bertrand Le Bourdonnec, Roland E. Dolle, Robert N. DeHaven, Diane L. DeHaven-Hudkins, Patrick J. Little and Jonathan M. Brotchie

    Version of Record online : 4 APR 2011, DOI: 10.1002/mds.23631

  11. The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates

    Movement Disorders

    Volume 25, Issue 13, 15 October 2010, Pages: 2084–2093, Tom H. Johnston, Susan H. Fox, Matthew J. Piggott, Juha-Matti Savola and Jonathan M. Brotchie

    Version of Record online : 7 SEP 2010, DOI: 10.1002/mds.23172

  12. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets

    Movement Disorders

    Volume 25, Issue 13, 15 October 2010, Pages: 2059–2066, Louisa Clare Johnston, Michael John Jackson, Sarah Rose, Andrew Christopher McCreary and Peter Jenner

    Version of Record online : 18 AUG 2010, DOI: 10.1002/mds.23249

  13. Molecular mechanisms underlying levodopa-induced dyskinesia

    Movement Disorders

    Volume 23, Issue S3, 2008, Pages: S570–S579, Paolo Calabresi, Massimiliano Di Filippo, Veronica Ghiglieri and Barbara Picconi

    Version of Record online : 9 SEP 2008, DOI: 10.1002/mds.22019

  14. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naïve primates

    Movement Disorders

    Volume 20, Issue 3, March 2005, Pages: 306–314, Lance A. Smith, Michael J. Jackson, Ghassan Al-Barghouthy, Sarah Rose, Mikko Kuoppamaki, Warren Olanow and Peter Jenner

    Version of Record online : 15 OCT 2004, DOI: 10.1002/mds.20317

  15. Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia?

    Fundamental & Clinical Pharmacology

    Volume 9, Issue 5, September-October 1995, Pages: 434–442, PJ Blanchet, B. Gomez-Mancilla, T. Di Paolo and PJ Bédard

    Version of Record online : 26 AUG 2009, DOI: 10.1111/j.1472-8206.1995.tb00518.x

  16. Clinical–Pathological study of levodopa complications

    Movement Disorders

    Volume 17, Issue 2, March/April 2002, Pages: 289–296, Azi H. Rajput, Mark E. Fenton, Sam Birdi, Rob Macaulay, David George, Bohdar Rozdilsky, Lee C. Ang, Ambikaipakan Senthilselvan and Oleh Hornykiewicz

    Version of Record online : 20 FEB 2002, DOI: 10.1002/mds.10031

  17. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)

    Movement Disorders

    Volume 16, Issue 4, July 2001, Pages: 631–641, Eleni C. Maratos, Michael J. Jackson, Ronald K. B. Pearce and Peter Jenner

    Version of Record online : 11 JUL 2001, DOI: 10.1002/mds.1149

  18. Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets

    European Journal of Neuroscience

    Volume 21, Issue 12, June 2005, Pages: 3240–3250, M. J. Hurley, M. J. Jackson, L. A. Smith, S. Rose and P. Jenner

    Version of Record online : 15 JUL 2005, DOI: 10.1111/j.1460-9568.2005.04169.x

  19. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease

    Movement Disorders

    Volume 26, Issue 13, November 2011, Pages: 2354–2363, Christopher Kobylecki, Michael P. Hill, Alan R. Crossman and Paula Ravenscroft

    Version of Record online : 23 SEP 2011, DOI: 10.1002/mds.23867

  20. Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats

    Movement Disorders

    Volume 21, Issue 5, May 2006, Pages: 646–653, Concepció Marin, Esther Aguilar and José A. Obeso

    Version of Record online : 25 JAN 2006, DOI: 10.1002/mds.20780